The Role Of Hsa-miR-500a-3p In Early Diagnosis And Course Judgement Of Prostate Cancer

BACKGROUND: Prostate cancer is the most common malignant tumor among men in Western countries,accounting for about 10% of the cancer mortality rate in the United States.In the UK,there are about 35,000 new cases of prostate cancer each year.Although the incidence of clinical prostate cancer in China is much lower than that in Western countries,the incidence of prostate cancer has been increasing year by year in recent years.Since the detection of plasma prostate specific antigen(PSA)has been applied to the screening of clinical prostate cancer,many asymptomatic patients with early prostate cancer have been diagnosed and treated.However,in recent years,most early-diagnosed prostate cancer belongs to inert prostate cancer,and patients will not die of prostate cancer even if they do not receive treatment,so active monitoring can be used to avoid overtreatment.If invasive prostate cancer can not be completely removed by radical resection in the early stage,even after androgen deprivation treatment,distant metastasis(such as bone)or progression to castration-resistant prostate cancer will eventually occur.Once the disease has reached this stage,there is no effective cure.Chemotherapy only benefits some patients,and only prolongs their survival for a few months.Therefore,actively screening specific genetic markers related to prognosis and drug resistance of prostate cancer,and exploring their predictive value and appropriate monitoring model of disease progression are hot issues in the field of prostate cancer research,which are of great significance for the treatment of early prostate cancer patients after diagnosis and the monitoring of drug efficacy.Objective:By detecting the stable expression of micro RNAs in circulating blood,it was proved that some differentially expressed micro RNAs in blood could be used as blood molecular markers for early diagnosis and course judgment of prostate cancer.To help early diagnosis,course judgement and prognostic evaluation of prostate cancer.WE find out stable differentially expressed micro RNA in circulating blood combined with clinical information(patient age,patient PSA value,Gleason score,etc.)Methods: Through high-throughput sequencing,micro RNAs differentially and stably expressed in benign prostatic hyperplasia,prostate cancer and healthy control group were screened out from 9 blood samples(3 of them were prostate cancer,3 of them were benign prostatic hyperplasia and 3 healthy persons).Blood samples from patients with prostate cancer and benign prostatic hyperplasia(45 patients with prostate cancer and 30 patients with benign prostatic hyperplasia)in our hospital were collected.The expression of micro RNA in blood was detected by PCR,and the micro RNA screened by clinical data analysis was of certain significance to determine whether the sequencing results of second generation sequencing were effective.The expression level of differentially expressed micro RNA in serum of each group and its relationship with clinicopathological parameters were analyzed.The blood samples used in the study were from patients without prostate cancer-related treatment.Results:Four stable differentially expressed microRNAs were screened from prostate cancer patients and benign prostatic hyperplasia patients with negative prostate puncture and healthy controls by second-generation high-throughput sequencing.Hsa-mir-500a-3p and hsa-mir-7854-3p were highly expressed in prostate cancer,hsa-mir-584-3p and hsa-mir-4725-3p were highly expressed in healthy persons and benign prostatic hyperplasia.The expression level of hsa-mir-500a-3p in serum of patients with prostate cancer was significantly higher than that of patients with benign prostatic hyperplasia and normal group,and the difference was statistically significant(P < 0.05).Compared with the normal group,the expression level of micro RNA-500a-3p in serum of BPH group was also significantly increased (P < 0.05).The expression of micro RNA-500a-3p in serum of patients with prostate cancer was closely related to pathological stage,clinical stage,bone metastasis and serum t PSA(P < 0.05),but not with age(P > 0.05).Conclusion:The expression level of micro RNA-500a-3p in serum of prostate cancer patients has changed significantly,which provides experimental basis for early diagnosis and judgment of the course of prostate cancer.Combined with clinical data such as PSA,prostate cancer can be diagnosed more accurately.